A detailed history of Bank Of New York Mellon Corp transactions in 2seventy Bio, Inc. stock. As of the latest transaction made, Bank Of New York Mellon Corp holds 158,792 shares of TSVT stock, worth $517,661. This represents 0.0% of its overall portfolio holdings.

Number of Shares
158,792
Previous 196,959 19.38%
Holding current value
$517,661
Previous $758 Million 1.16%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

SELL
$3.85 - $5.05 $146,942 - $192,743
-38,167 Reduced 19.38%
158,792 $749 Million
Q2 2024

Jul 25, 2024

BUY
$3.6 - $5.79 $36,277 - $58,345
10,077 Added 5.39%
196,959 $758 Million
Q1 2024

Apr 25, 2024

SELL
$3.09 - $6.0 $33,211 - $64,488
-10,748 Reduced 5.44%
186,882 $1 Billion
Q4 2023

Jan 29, 2024

BUY
$1.57 - $4.58 $25,595 - $74,667
16,303 Added 8.99%
197,630 $844 Million
Q3 2023

Oct 24, 2023

SELL
$3.14 - $11.2 $9,084 - $32,401
-2,893 Reduced 1.57%
181,327 $711 Million
Q2 2023

Aug 03, 2023

BUY
$8.45 - $12.48 $371,098 - $548,084
43,917 Added 31.3%
184,220 $1.86 Billion
Q1 2023

May 09, 2023

BUY
$9.21 - $14.98 $1.29 Million - $2.1 Million
140,303 New
140,303 $1.43 Billion
Q4 2022

Feb 14, 2023

BUY
$8.57 - $17.0 $1.15 Million - $2.29 Million
134,426 New
134,426 $1.26 Million
Q3 2022

Nov 14, 2022

BUY
$12.56 - $17.54 $118,779 - $165,875
9,457 Added 7.41%
137,038 $1.99 Million
Q2 2022

Aug 15, 2022

BUY
$10.55 - $18.81 $422,886 - $753,980
40,084 Added 45.81%
127,581 $1.68 Million
Q1 2022

May 11, 2022

SELL
$11.67 - $26.72 $26,735 - $61,215
-2,291 Reduced 2.55%
87,497 $1.49 Million
Q4 2021

Feb 11, 2022

BUY
$13.77 - $42.56 $1.24 Million - $3.82 Million
89,788 New
89,788 $2.3 Million

Others Institutions Holding TSVT

About 2seventy bio, Inc.


  • Ticker TSVT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 37,873,600
  • Market Cap $123M
  • Description
  • 2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. Its products pipeline includes idecabtagene vicleucel; ide-cel or Abecma and bb21217; and CAR-T cell product candidates for the treatment of multiple myeloma. 2seventy bio, Inc. has a col...
More about TSVT
Track This Portfolio

Track Bank Of New York Mellon Corp Portfolio

Follow Bank Of New York Mellon Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of New York Mellon Corp, based on Form 13F filings with the SEC.

News

Stay updated on Bank Of New York Mellon Corp with notifications on news.